Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months
Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months
复制标题
DOI：
10.1089/cap.1998.8.151
复制
发表时间：
1998-01-01
影响因子：
1.9
通讯作者：
Ushchak, CM
中科院分区：
文献类型：
--
作者：
Kelly, DL;Conley, RR;Ushchak, CM
体重增加是抗精神病药物治疗的严重副作用。肥胖的潜在后果包括不依从药物治疗以及显著的发病率和死亡率。由于非典型抗精神病药物越来越多地用于青少年，因此确定并进一步描述该人群的体重增加率非常重要。这项研究比较了青少年使用常规抗精神病药物与利培酮相关的体重增加。这项回顾性研究确定了60名青少年住院患者，他们服用利培酮（n = 18），传统的抗精神病药物（n = 23），或没有抗精神病药物（n = 19）。在6个月的时间内记录每月的身高和体重测量值，以计算体重指数（BMI）值。在6个月的观察期内，接受利培酮治疗的受试者平均体重增加8.64 kg，体重增加3.67 kg/m2。服用常规抗精神病药物的患者体重增加了3.03 kg或0.31 kg/m2，而对照组在同一时间段内实际体重减轻了（-1.04 kg或-1.01 kg/m2）。尽管两组抗精神病药物组的体重和BMI均增加，但利培酮治疗组的体重增加明显多于常规抗精神病药物组（p = 0.0011）。体重增加与剂量无关，伴随用药（如兴奋剂和锂）不会导致BMI变化。
Weight gain is a serious side effect of antipsychotic therapy. Potential consequences of obesity include noncompliance with medications as well as significant morbidity and mortality. Because atypical antipsychotic agents are increasingly being used in adolescents, it is important to determine and further characterize the rate of weight gain in this population. This study compares weight gain associated with the use of conventional antipsychotic agents with that seen with risperidone in adolescents. This retrospective study identified 60 adolescent inpatients who were taking risperidone (n = 18), conventional neuroleptics (n = 23), or no antipsychotic medication (n = 19). Monthly height and weight measurements were recorded over a 6-month period, allowing body mass index (BMI) values to be calculated. Subjects treated with risperidone gained a mean of 8.64 kg and increased in body mass by 3.67 kg/m(2) over the 6-month observation period. Those taking conventional antipsychotics gained 3.03 kg or 0.31 kg/m(2) in body mass, whereas the control group actually lost weight (-1.04 kg, or -1.01 kg/m(2)) in the same time frame. Although both antipsychotic groups gained in weight and BMI, the risperidone-treated group gained significantly more body mass than did the conventional antipsychotic group (p = 0.0011). Gains in body weight did not correlate with dose, and concomitant medications such as stimulants and lithium did not contribute to changes in BMI.